Merck and Ridgeback Biotherapeutics COVID-19 News
Merck (MRK) and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801) - an investigational oral antiviral medicine, has significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized . . .
This content is for paid subscribers.
Impacting News
October 1, 2021
